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Introduction
Cystic lesions in the parapharyngeal space are rare. When they do occur, they typically arise from the parotid gland and the first and second pharyngeal pouches. Generally, these lesions manifest as neck masses; sometimes they are asymptomatic, but more often they are accompanied by an abscess formation.
To the best of our knowledge, only 23 cases of a branchial cyst in the parapharyngeal space have been heretofore described in the literature (table) .':" In this article, we report an additional case, and we discuss the diagnosis and treatment of this lesion.
Case report
A 65-year-old man reported that he had been experiencing dysphagia and sore throat for the previous 20 days. He had been treated with antibiotics and anti-inflammatory drugs at another medical center, but when these treatments failed to relieve his condition, he came to our facility.
On physical examination, we observed in the oropharynx a fluctuating mass that was covered with normal mucosa. On fiberoscopy, we noted that the mass had extended to the right torus tubarius in the nasopharynx and to the level of the epiglottic tip on the lateral wall of the hypopharynx. The lesion was estimated to be 3 x 2 em based on palpation of the neck between the angle of the mandible and the anterior border of the right sternocleidomastoid muscle. Findings on otoscopic examination were normal bilaterally. Computed tomography (CT) revealed that a 3.8 x 7.0-cm cystic mass was obstructing the oropharynx and filling the parapharyngeal and retropharyngeal spaces on the right (figure).
The patient was administered general anesthesia and underwent surgery via a transcervical approach. After decompression, the cyst wall was excised. The aspirate consisted of clear fluid. Histopathologic examination was consistent with a branchial cleft cyst. The patient experienced no postoperative complications, and no recurrence had been detected at 2 years' followup.
Discussion
A number of reports on cysts in the lateral pharyngeal area suggest that they have a branchial origin. These lesions expand through the cervical planes and manifest as submucosal lateral pharyngeal masses; they generally have a cervical component. The most common symptoms are sore throat, dysphagia, dysarthria, and dyspnea. In most cases, an accompanying infection leads to an abscess formation, which adds pain, fever, and cervical stiffness to the list of symptoms. In rare instances, paresis of the cranial nerves that pass through the parapharyngeal space has been observed.":"
Imaging techniques establish the site of origin of these lesions with a 96% accuracy.'? In order to ascertain the best surgical approach, it is necessary to distinguish deeplobe parotid lesions from extraparotid lesions." CT with contrast is valuable in accurately identifying the location and extent of the tumor and is occasionally helpful in determining the nature of the lesion. 18 -2o Magnetic resonance imaging (MRI) is the best radiologic technique for evaluating parapharyngeal space lesions. With its highresolution capacity, MRI can establish the precise limits 7.5%
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Treatment for Negative Pressure and Otitis
The Otovent method is designed to treat many of the complications associated with negative ear pressure caused by Eustachian tube dysfunction.
• Otovent can prevent or treat Otitis media and can be an alternative to surgery.
• Proven success in clinical study. There are two theories regarding the etiology of internal branchial cysts, The first suggests that they are derived from the branchial apparatus." The second theory considers the presence of subepithelial lymphocytes and suggests that the cysts are derived from ectopic epithelial cells in the regional lymph nodes." In our case, the cystic wall was lined with columnar epithelium without lymphocyte infiltration. Furthermore, the site of the pharyngeal attachment and the lack of deformity in derivatives of the first branchial apparatus support the view that this cyst originated in the second branchial apparatus.
